In the context of TT as an anticancer therapy, we hypothesise that the disruption of tumour tissues and blood supply that was seen in animal models [1,8] may be linked to the ability of TT to disrupt epithelial—and likely also endothelial—Nectin-family members due to irreversible cleavage. This evidence concerns the gene NECTIN1 and neoplasm.